Exploiting the advantages revealed in these trials, we discovered that the CXCR1/CXCR2 antagonist SX682 (currently in phase I/II clinical trials for metastatic colorectal adenocarcinoma) and the CXCR2-specific inhibitor Danirixin (currently entering phase II clinical trials for pulmonary disease) effectively inhibited EV-D68 RNA replication (Fig. 3e and j). This evidence concerns the gene CXCR2 and lung disorder.